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Confounding Factors Affecting sRAGE as a Biomarker
for Chronic Obstructive Pulmonary Disease
To the Editor:
In a review paper recently published in the Journal, Stockley and
colleagues provide an excellent overview of the current literature and the
necessity and limitations of currently available and future chronic
obstructive pulmonary disease (COPD) biomarkers (1). In their review,
Stockley and colleagues state that the circulating level of sRAGE (soluble
receptor for advanced glycation end-products) is the best known
biomarker for the COPD phenotype emphysema, yet some limitations
prohibit the current use of sRAGE in the clinic, including large
interindividual variation with overlap between healthy controls and
patients with COPD and limited knowledge on confounding factors
such as smoking behavior. Although Stockley and colleagues provide a
thorough overview of the currently available data on sRAGE as a
biomarker for COPD, they overlooked key publications by our group
on the role of sRAGE as a COPD biomarker. Stockley and colleagues
speculate about the potential effects of smoking on circulating sRAGE
levels, and state that this needs to be investigated further. In fact, we
have recently addressed these issues, as we have shown that smoking
acutely and severely decreases serum sRAGE levels by up to 50% within
2 hours after smoking three cigarettes (2). We validated these results
using two distinct quantitative sRAGE assays to exclude the possibility
of a technical artifact. Furthermore, in a second study, we showed that
this difference is not caused by chronic smoke exposure, as we did not
ﬁnd signiﬁcant differences in serum sRAGE levels among age-, sex-,
and body mass index–matched, young and old smokers and never
smokers (3, 4). These data indicate that smoking acutely and
temporarily decreases serum sRAGE levels, which may cause large
interindividual variations in serum sRAGE levels, as reviewed by
Stockley and colleagues. Therefore, we proposed that smoking cessation
in the hours before blood sampling may decrease the variation in serum
sRAGE levels and increase the discriminative value of sRAGE as a
biomarker for COPD. Furthermore, Stockley and colleagues state that
more studies are needed investigating the effect of COPD exacerbations
on serum sRAGE levels. Indeed, we investigated this using serum
samples of 14 patients with COPD that were in stable disease,
and serum samples from the same patients when they were
experiencing an exacerbation (5). Here, we showed that serum sRAGE
levels are signiﬁcantly decreased during an exacerbation, although
there is no difference in the expression of the gene encoding RAGE in
granulocytes. In summary, our results are in line with Stockley and
colleagues, that more research on confounding factors is needed before
sRAGE can be implemented as a clinically usable COPD biomarker.n
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Reply to Pouwels et al.
From the Authors:
We welcome the letter from Pouwels and colleagues, who provide
recent and historical evidence to amplify the issues related to the role
of smoking and exacerbations in the interpretation of sRAGE
(soluble receptor for advanced glycation end-products) data (and
This article is open access and distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives License 4.0
(http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage
and reprints, please contact Diane Gern (dgern@thoracic.org).
Supported by the Netherlands Organization for Scientific Research NWO
(Domain Applied and Engineering Sciences; Perspectief program P12-04;
projects: 13541 and 13544) and the Lung Foundation Netherlands (project:
6.2.15.044JO).
Author Contributions: S.D.P., F.K., R.B., and N.H.T.t.H. provided
the conception and design of the study; S.D.P. provided the drafting of the
manuscript; and S.D.P., F.K., R.B., and N.H.T.t.H. provided revision of the
manuscript.
Originally Published in Press as DOI: 10.1164/rccm.201902-0356LE on
March 19, 2019
This article is open access and distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives License 4.0
(http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage
and reprints, please contact Diane Gern (dgern@thoracic.org).
Author Contributions: R.A.S. wrote the initial response. D.H., B.R.C., and
D.S. critically appraised and added to the content, and approved the final
submission.
Originally Published in Press as DOI: 10.1164/rccm.201903-0573LE on
March 19, 2019
CORRESPONDENCE
114 American Journal of Respiratory and Critical Care Medicine Volume 200 Number 1 | July 1 2019
